Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC50 = 0.04 μM) with decent antiviral potency (EC50 = 7.4 μM) and no cytotoxicity (CC50 > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC50 = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retroviral integrase superfamily: the structural perspective
Nowotny, M. (2009) · The EMBO Reports · doi:10.1038/embor.2008.256 · Cited by 183 · cited 1×
“In addition, RNase H shares a similar active site fold and mechanism of catalysis with HIV IN [28].”
BackgroundHIV-1 ribonuclease H: structure, catalytic mechanism and inhibitors
Beilhartz, G. L., & Götte, M. (2010) · Viruses · doi:10.3390/v2040900 · Cited by 88 · cited 1×
“domains [27], inhibition of RNase H is often accompanied by the inhibition of RT pol.”
Kankanala, J., Kirby, K. A., Liu, F., Miller, L., Nagy, E., Wilson, D. J., Parniak, M. A., Sarafianos, S. G., & Wang, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00465 · Cited by 66 · cited 2×
“These include diketoacids (1) [10], 2-hydroxyisoquinoline-1,3-diones (HID, 2) [11–13], hydroxylated tropolones (3) [14], pyrimidinol carboxylic acids (4) [3], hydroxypyridone carboxylic acids (5) [15], hydroxynaphthyridines (6) [16], and pyridopyrimidones (7) [17].”
BackgroundResultSelf-citationRecent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Research works printed but not linked: 53
- Fuji, 2009, Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase, J. Med. Chem., 52, 1380, 10.1021/jm801071m · DOI
- Kirschberg, 2009, RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information, J. Med. Chem., 52, 5781, 10.1021/jm900597q · DOI · Paper page
- Kang, 2014, “Old dogs with new tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets, Mol. Biosyst., 10, 1998, 10.1039/C4MB00147H · DOI
- Cihlar, 2010, Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine, Antivir. Res., 85, 39, 10.1016/j.antiviral.2009.09.014 · DOI · Paper page
- de Bethune, 2010, Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009), Antivir. Res., 85, 75, 10.1016/j.antiviral.2009.09.008 · DOI · Paper page
- Yu, 2008, Recent advances in the research of HIV-1 RNase H inhibitors, Mini. Rev. Med. Chem., 8, 1243, 10.2174/138955708786141052 · DOI
- Wang, 2017, Update on recent developments in small molecular HIV-1 RNase H inhibitors (2013-2016): opportunities and challenges, Curr. Med. Chem., 24
- Shaw-Reid, 2003, Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-5-(benzoylamino)thien-2-yl -2,4-dioxobutanoic acid, J. Biol. Chem., 278, 2777, 10.1074/jbc.C200621200 · DOI · Paper page
- Klumpp, 2003, Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors, Nucleic Acids Res., 31, 6852, 10.1093/nar/gkg881 · DOI · Paper page
- Vernekar, 2015, Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities, J. Med. Chem., 58, 651, 10.1021/jm501132s · DOI · Paper page
- Tang J, 2017, Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase, Eur. J. Med. Chem., 133, 85, 10.1016/j.ejmech.2017.03.059 · DOI
- Himmel, 2009, Structure of HIV-1 reverse transcriptase with the inhibitor beta-thujaplicinol bound at the RNase H active site, Structure, 17, 1625, 10.1016/j.str.2009.09.016 · DOI · Paper page
- Williams, 2010, Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold, Bioorg. Med. Chem. Lett., 20, 6754, 10.1016/j.bmcl.2010.08.135 · DOI
- Beilhartz, 2014, Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation, J. Biol. Chem., 289, 16270, 10.1074/jbc.M114.569707 · DOI · Paper page
- Tang, 2016, 3-Hydroxypyrimidine-2,4-diones as selective active site inhibitors of HIV reverse transcriptase-associated RNase H: design, synthesis, and biochemical evaluations, J. Med. Chem., 59, 2648, 10.1021/acs.jmedchem.5b01879 · DOI
- Wu, 2016, 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H, J. Med. Chem., 59, 6136, 10.1021/acs.jmedchem.6b00040 · DOI
- Tang, 2017, 6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverse transcriptase: impacts of the 3-OH on inhibiting RNase H and polymerase, Eur. J. Med. Chem., 128, 168, 10.1016/j.ejmech.2017.01.041 · DOI
- Tumey, 2005, The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors, Bioorg. Med. Chem. Lett., 15, 277, 10.1016/j.bmcl.2004.10.086 · DOI
- Kankanala, 2016, Isoquinoline-1,3-diones as selective inhibitors of tyrosyl DNA phosphodiesterase II (TDP2), J. Med. Chem., 59, 2734, 10.1021/acs.jmedchem.5b01973 · DOI
- Chen, 2012, The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus, Bioorg. Med. Chem., 20, 467, 10.1016/j.bmc.2011.10.058 · DOI
- Lanier, 2007, Selection, synthesis, and structure-activity relationship of tetrahydropyrido 4,3-dipyrimidine-2,4-diones as human GnRH receptor antagonists, Bioorg. Med. Chem., 15, 5590, 10.1016/j.bmc.2007.05.029 · doi:10.1016/j.bmc.2007.05.029
- Briel, 2010, Substituted 2-aminothiopen-derivatives: a potential new class of GluR6-antagonists, Eur. J. Med. Chem., 45, 69, 10.1016/j.ejmech.2009.09.025 · doi:10.1016/j.ejmech.2009.09.025
- Osman, 2016, Discovery of novel tetrahydrobenzo b thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: the structural elements controlling binding affinity, selectivity and functionality, Eur. J. Med. Chem., 122, 619, 10.1016/j.ejmech.2016.07.012 · DOI
- Sirivolu, 2013, Clicking 3 '-azidothymidine into novel potent inhibitors of human immunodeficiency virus, J. Med. Chem., 56, 8765, 10.1021/jm401232v · DOI
- Himmel, 2006, HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site, ACS Chem. Biol., 1, 702, 10.1021/cb600303y · DOI · Paper page
- Johns, 2013, Carbamoyl pyridone HIV-1 integrase inhibitors 3. a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744), J. Med. Chem., 56, 5901, 10.1021/jm400645w · DOI · Paper page
- Friesner, 2006, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem., 49, 6177, 10.1021/jm051256o · DOI · Paper page
- Huang, 1998, Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: implications for drug resistance, Science, 282, 1669, 10.1126/science.282.5394.1669 · DOI · Paper page
- Sarafianos, 2001, Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA, EMBO J., 20, 1449, 10.1093/emboj/20.6.1449 · DOI · Paper page
- Sarafianos, 2002, Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA, EMBO J., 21, 6614, 10.1093/emboj/cdf637 · DOI · Paper page
- Kirby, 2017, A 2-hydroxyisoquinoline-1,3-dione active site RNase H inhibitor binds in multiple modes to HIV-1 reverse transcriptase, Antimicrob. Agents Chemother., 61, 10.1128/AAC.01351-17 · DOI
- Fletcher, 1996, Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase, Protein Expr. Purif., 7, 27, 10.1006/prep.1996.0004 · DOI
- Parniak, 2003, A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity, Anal. Biochem., 322, 33, 10.1016/j.ab.2003.06.001 · DOI
- Vernekar, 2017, Double-winged 3-hydroxypyrimidine-2,4-diones: potent and selective inhibition against HIV-1 RNase H with significant antiviral activity, J. Med. Chem., 60, 5045, 10.1021/acs.jmedchem.7b00440 · DOI · Paper page
- Wang, 2007, Rationally designed dual inhibitors of HIV reverse transcriptase and integrase, J. Med. Chem., 50, 3416, 10.1021/jm070512p · DOI · Paper page
- Abram, 2005, Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain, J. Virol., 79, 11952, 10.1128/JVI.79.18.11952-11961.2005 · DOI · Paper page
- Sastry, 2013, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des., 27, 221, 10.1007/s10822-013-9644-8 · DOI · Paper page
- Jorgensen, 1996, Development and testing of the OPLS all- atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc., 118, 11225, 10.1021/ja9621760 · DOI · Paper page
- Kirby, 2012, Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase, Antimicrob. Agents Chemother., 56, 2048, 10.1128/AAC.06000-11 · DOI
- Bauman, 2008, Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design, Nucleic Acids Res., 36, 5083, 10.1093/nar/gkn464 · DOI · Paper page
- Winter, 2013, Decision making in xia2, Acta Crystallogr. D. Biol. Crystallogr., 69, 1260, 10.1107/S0907444913015308 · DOI · Paper page
- Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
- Matthews, 1985, Determination of protein molecular-weight, hydration, and packing from crystal density, Methods Enzymol., 114, 176, 10.1016/0076-6879(85)14018-8 · DOI
- Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr. D. Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
- Keegan, 2008, MrBUMP: an automated pipeline for molecular replacement, Acta Crystallogr. D. Biol. Crystallogr., 64, 119, 10.1107/S0907444907037195 · DOI · Paper page
- Bauman, 2013, Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening, J. Med. Chem., 56, 2738, 10.1021/jm301271j · DOI · Paper page
- Cowtan, 2006, The Buccaneer software for automated model building. 1. Tracing protein chains, Acta Crystallogr. D. Biol. Crystallogr., 62, 1002, 10.1107/S0907444906022116 · DOI · Paper page
- Cowtan, 2010, Recent developments in classical density modification, Acta Crystallogr. D. Biol. Crystallogr., 66, 470, 10.1107/S090744490903947X · DOI · Paper page
- Emsley, 2010, Features and development of Coot, Acta Crystallogr. D. Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
- Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. D. Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
- Pannu, 1998, Incorporation of prior phase information strengthens maximum-likelihood structure refinement, Acta Crystallogr. D. Biol. Crystallogr., 54, 1285, 10.1107/S0907444998004119 · DOI · Paper page
- Murshudov, 2011, REFMAC5 for the refinement of macromolecular crystal structures, Acta Crystallogr. D. Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314 · DOI · Paper page
- Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D. Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
Cited by
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Self-citationWang, L., Sarafianos, S. G., & Wang, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00450 · Cited by 43
Self-citationWang, L., Tang, J., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Xie, J., Parniak, M. A., Sarafianos, S. G., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.039 · Cited by 36
“Our efforts based on the aforementioned pharmacophore model have led to the discovery of four distinct chemotypes (8–11, Figure 1, B), including the redesigned HID subtype 8,[19] the hydroxypyridonecarboxylic acid (HPCA) chemotype 9,[20] the redesigned HPD subtype 10, [21] and the N-hydroxy thienopyrimidine-2,4-dione…”
BackgroundSelf-citationRetroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
Metadata
- Authors
- Kankanala, J., Kirby, K. A., Huber, A. D., Casey, M. C., Wilson, D. J., Sarafianos, S. G., & Wang, Z.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 141
- Pages
- 149-161
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2756623713
- Cited by
- 44
- References
- 4
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 315 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Institutes of Health (AI100890)
- Research Development and Seed Grant Program of the Center for Drug Design, University of Minnesota
- U.S. DOE (DE-AC02-06CH11357)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. https://app.cochat.ai/papers/10.1016/j.ejmech.2017.09.054
- The paper
- Kankanala, J., Kirby, K. A., Huber, A. D., Casey, M. C., Wilson, D. J., Sarafianos, S. G., & Wang, Z. (2017). Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2017.09.054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.